Adicet Bio 3Q 2026: EPS ($1.76) — 10-Q Summary

Adicet Bio’s third-quarter net loss narrowed year over year as research and development and general and administrative expenses fell. Lower headcount and reduced CRO costs, including no new patient enrollment, drove much of the R&D decline; lower stock-based compensation and headcount reduced G&A e…